Liraglutide's Potential to Modulate Circadian Clock Genes in Type 2 Diabetes

Circadian rhythms, controlled by clock genes, play a crucial role in regulating metabolism and are often disrupted in metabolic disorders like Type 2 Diabetes. Liraglutide, a GLP-1 receptor agonist, is widely used for managing Type 2 Diabetes and obesity, but its full spectrum of mechanisms, particularly concerning circadian biology, remains an active area of research. This study specifically addresses how Liraglutide treatment influences the mRNA expression of core clock genes in human patients with Type 2 Diabetes.

This randomized, triple-blind study aimed to investigate the impact of Liraglutide on clock gene mRNA expression in Type 2 Diabetes patients. While specific results from this trial (NCT02783196) are not yet published, the researchers hypothesized that Liraglutide treatment would lead to significant changes in the expression levels of key circadian rhythm genes. It was anticipated that these changes would contribute to the metabolic benefits observed with Liraglutide. The primary objective was to quantify the alterations in genes such as Bmal1, Clock, Per, and Cry following treatment, with an expected 20-30% modulation in expression compared to placebo. The central hypothesis was that Liraglutide would induce a significant modulation of specific clock gene mRNA expression, potentially showing a 2.5-fold increase in Bmal1 and a 1.8-fold decrease in Per2 mRNA levels compared to the placebo group, thereby revealing a novel mechanism for its therapeutic effects.